1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.
2. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001 Nov;24(11):1858-62.
3. Kaufman FR, Austin J, Neinstein A, Jeng L, Halvorson M, Devoe DJ, Pitukcheewanont P. Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. J Pediatr. 2002 Nov;141(5):625-30.
4. Danne T, Lange K, Kordonouri O. Real-time glucose sensors in children and adolescents with type-1 diabetes. Horm Res. 2008;70(4):193-202.
5. Hermanides J, DeVries JH. Sense and nonsense in sensors. Diabetologia. 2010 Apr;53(4):593-6.
6. Hirsch IB, Armstrong D, Bergenstal RM, Buckingham B, Childs BP, Clarke WL, Peters A, Wolpert H. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol Ther. 2008 Aug;10(4):232-44.
7. Ives B, Sikes K, Urban A, Stephenson K, Tamborlane WV. Practical aspects of real-time continuous glucose monitors: the experience of the Yale Children’s Diabetes Program. Diabetes Educ. 2010 Jan-Feb;36(1):53-62.
8. Keenan DB, Cartaya R, Mastrototaro JJ. Accuracy of a new real-time continuous glucose monitoring algorithm. J Diabetes Sci Technol. 2010 Jan 1;4(1):111-8.
9. Tubiana-Rufi N, Riveline JP, Dardari D. Realtime continuous glucose monitoring using GuardianRT: from research to clinical practice. Diabetes Metab. 2007 Dec;33(6):415-20.
10. Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo- Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O’Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer SA, Wilson DM, Wolpert H, Wysocki T, Xing D. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009 Aug;32(8):1378-83.
11. Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, Chase HP, Hirsch I, Kollman C, Laffel L, Lawrence JM, Milaszewski K, Ruedy KJ, Tamborlane WV. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009 Nov;32(11):1947-53.
12. Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Tamborlane WV, Weinzimer S, Wolpert H. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009 Nov;32(11):2047-9.
13. Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK,Ellis SL. Continuous home monitoring of glucose: improved glycemic control with reallife use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007 Dec;30(12):3023-5.
14. O’Connell MA, Donath S, O’Neal DN, Colman PG, Ambler GR, Jones TW, Davis EA, Cameron FJ. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009 Jul;52(7):1250-7.
15. Peyrot M, Rubin RR. Patient-reported outcomes for an integrated real-time continuous glucose monitoring/insulin pump system. Diabetes Technol Ther. 2009 Jan;11(1):57-62.
16. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O’Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76.
17. Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy KJ, Tansey M, Weinzimer SA, Wysocki T. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007 Oct;151(4):388-93.
18. Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes. 2009 Apr;10(2):91-6.
19. The Diabetes Research in Children Network (DirecNet) Study Group. Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetes. Pediatr Diabetes. 2006 Feb;7(1):32-8.
20. Cemeroglu AP, Stone R, Kleis L, Racine MS, Postellon DC, Wood MA. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients’ and caregivers’ perception of benefit. Pediatr Diabetes. 2010 May;11(3):182-7.
21. Tucholski K, Deja G, Skała-Zamorowska E, Jarosz-Chobot P. Evaluation of daily glycemic profiles in well controlled children with type 1 diabetes mellitus using a continuous glucose monitoring system. Pediatr Endocrinol Diabetes Metab. 2009;15(1):29-33.
22. Battelino T. Prolonged use of continuous glucose monitoring: kids do not listen-says who? Pediatr Diabetes. 2009 Apr; 10(2):89-90.
23. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008 Feb;24(2):87-92.
24. Thompson CJ, Cummings JF, Chalmers J, Gould C, Newton RW. How have patients reacted to the implications of the DCCT? Diabetes Care. 1996 Aug;19(8):876-9.
25. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007 Jun;9(3):203-10.
26. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006 Dec;29(12):2730-2.
27. Hoeks LB, Greven WL, de Valk HW. Realtime continuous glucose monitoring system for treatment of diabetes: a systematic review. Diabet Med. 2011 Apr;28(4):386-94.
28. Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2012 Feb;13(1):6-11.
29. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care. 2009 Dec;32(12):2245-50.
30. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. Jama. 2006 Apr 12; 295 (14): 1707-8.
31. McDonnell CM, Northam EA, Donath SM, Werther GA, Cameron FJ. Hyperglycemia and externalizing behavior in children with type 1 diabetes. Diabetes Care. 2007 Sep;30(9):2211-5.
32. Danne T, de Valk HW, Kracht T, Walte K, Geldmacher R, Solter L, von dem Berge W, Welsh ZK, Bugler JR, Lange K, Kordonouri O. Reducing glycaemic variability in type 1 diabetes self-management with a continuous glucose monitoring system based on wired enzyme technology. Diabetologia. 2009 Aug;52(8):1496-503.
33. Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008 Oct;10(5):377-83.
34. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan;29(1):44-50.
35. Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther. 2009 Nov;11(11):717-23.
36. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. Apr;34(4):795-800.
37. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care. 2006 Dec;29(12):2644-9.
38. Davey RJ, Jones TW, Fournier PA. Effect of shortterm use of a continuous glucose monitoring system with a real-time glucose display and a low glucose alarm on incidence and duration of hypoglycemia in a home setting in type 1 diabetes mellitus. J Diabetes Sci Technol. 2010 Nov 1;4(6):1457-64.
39. Yoo HJ, An HG, Park SY, Ryu OH, Kim HY, Seo JA, Hong EG, Shin DH, Kim YH, Kim SG, Choi KM, Park IB, Yu JM, Baik SH. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2008 Oct;82(1):73-9.
40. Halvorson M, Carpenter S, Kaiserman K, Kaufman FR. A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump. J Pediatr. 2007 Jan;150(1):103-105.
41. Rubin RR, Peyrot M. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/ insulin pump system compared to self-monitoring plus an insulin pump. J Diabetes Sci Technol. 2009 Nov;3(6):1402-10.
Volume 58 (2013)
Volume 57 (2012)
Volume 56 (2011)
Volume 55 (2010)
Volume 54 (2009)
Most Downloaded Articles
- Magnetic nanoparticles as new diagnostic tools in medicine by Niemirowicz, K/ Markiewicz, KH/ Wilczewska, AZ and Car, H
- Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: When is it indicated, what is the goal and how to do it? by Domínguez-Muñoz, J
- Current overview of functions of FoxO proteins, with special regards to cellular homeostasis, cell response to stress, as well as inflammation and aging by Wątroba, M/ Maślińska, D and Maśliński, S
- Probiotic-induced apoptosis and its potential relevance to mucosal inflammation of gastrointestinal tract by Daniluk, U/ Alifier, M and Kaczmarski, M
- Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines by Li, H/ Schmid-Bindert, G/ Wang, D/ Zhao, Y/ Yang, X/ Su, B and Zhou, C
Monthly use of a real-time continuous glucose monitoring system as an educational and motivational tool for poorly controlled type 1 diabetes adolescents
1Department of Paediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Bialystok,Waszyngtona 17, 15-274 Bialystok, Poland, Tel./Fax: +48 85 7450 730
2Department of Paediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Bialystok, Poland
Citation Information: Advances in Medical Sciences. Volume 0, Issue 0, Pages 1–9, ISSN (Online) 1898-4002, ISSN (Print) 1896-1126, DOI: 10.2478/ams-2013-0024, August 2013
- Published Online:
Purpose: Experience with the use of real-time continuous glucose monitoring systems (RT-CGMS) in teenagers with type 1 diabetes mellitus (T1DM) is limited. We aimed to assess the possibility of glycaemic control improvement and to characterize the group of adolescents, who may gain long-term benefits from the use of the RT-CGMS.
Methods and methods: Forty T1DM patients, aged 14.6±2.1 years, with diabetes duration 7.4±3.6 years and initial HbA1c 9.3±1.5% were recruited. The analysis was based on one-month glucose sensors use, combined with the thorough family support. Patients were analysed in groups according to baseline HbA1c: below and above 7.5%, and 10.0%. Comparison between patients with or without improvement in HbA1c after 3-month follow-up was also performed. Patients’ satisfaction based on the questionnaire was assessed.
Results: HbA1c level in entire study group decreased after three months, from 9.3±1.0% to 8.8±1.6% (P<0.001). In the group with HbA1c improvement, reduction was the highest: 9.0±1.3% vs. 8.0±1.2% (P<0.001). Only the group with initial HbA1c>10% did not achieve significant improvement: 11.2±0.5% vs. 10.9±1.1 (P=0.06). In satisfaction questionnaire the lowest scores (negative opinion) were reported by group of patients with initial HbA1c above 10%, while the highest scores (positive opinion) were found in the group with improvement of HbA1c after 3 month follow-up.
Conclusion: Short-term use of CGMS RT, united with satisfaction questionnaire, performed in poorly controlled teenagers with T1DM, can be useful in defining the group of young patients, who can benefit from long-term CGMS RT use in metabolic control improvement.